Markets Edge — Capital flows, CMO moves, M&A

ISABELLA'S ISLAY Capital Markets Jun 20, 11:02 AM EDT

SpaceX

SpaceX IPO opened at $75B valuation, retail access controlled by six platforms

SpaceX's initial public offering priced at $75 billion, with retail shares distributed exclusively through Charles Schwab, Fidelity, Robinhood, SoFi, Morgan Stanley's E-Trade, and one additional platform, marking an unconventional distribution model.

ReadingThe mega-IPO gatekeeping model works. Retail participation through appointed brokers is the new standard for founder-led exits at this scale.

WatchWatch which brokers report highest retail demand. Their client base will define the next unicorn's pre-IPO cap table.

Read full analysis → Original ↗

spacexipocapital marketsmega-deal

HENRI IV M&A Intelligence Jun 20, 11:02 AM EDT

SoftBank Group

Business Wire ↗

SoftBank filed tender offer for BALYO, ad hoc committee installed

SoftBank Group has filed a draft public tender offer for BALYO with the AMF (French securities regulator), with the target's board establishing an independent ad hoc committee composed of Ms. Juliette Favre and additional directors to evaluate the proposal.

ReadingSoftBank is consolidating mid-market logistics automation. BALYO's valuation will reset the category floor for AGVs and autonomous materials handling.

WatchWatch the independent committee's recommendation timing. French regulatory approval typically takes 90 days from filing.

Read full analysis → Original ↗

softbankbalyoautomationm&a

MACALLAN 1926 Healthcare Intelligence Jun 20, 11:02 AM EDT

Lisata Therapeutics

Business Insider Markets ↗

Kuva Labs commenced tender for Lisata at $4.00 per share plus CVR

Lisata Therapeutics stockholders will receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right representing additional potential consideration based on future milestones.

ReadingSmall-cap biotech valuations are anchored to cash runway, not pipeline potential. Milestone-based consideration signals the buyer does not believe near-term execution risk.

WatchWatch if the CVR triggers are clinical or commercial milestones. Clinical triggers mean Kuva expects Lisata's pipeline to require more capital.

Read full analysis → Original ↗

lisatakuva labsbiotechm&a

LOUIS XIII M&A Intelligence Jun 20, 11:02 AM EDT

DoubleDragon Corp.

MSN Money Philippines ↗

DoubleDragon lifted MerryMart stake to 98.6% via tender offer

DoubleDragon Corp., chaired by Edgar 'Injap' Sia II and Tony Tan Caktiong, secured strong shareholder support through a tender offer that elevated its stake in MerryMart to 98.6%, moving toward full operational control.

ReadingSoutheast Asian family offices are consolidating retail holdings before regional equity markets mature. MerryMart is now a private asset with a public shell.

WatchWatch for delisting announcement within 12 months. At 98.6% ownership, stock exchange requirements become negotiable.

Read full analysis → Original ↗

doubledragonmerrymartphilippinesretail

PAPPY 23 Healthcare Intelligence Jun 20, 11:02 AM EDT

Adverum Biotechnologies

NASDAQ / Globe Newswire ↗

Adverum reminded shareholders to tender into Lilly's pending acquisition

Adverum Biotechnologies issued a shareholder reminder to tender shares into the public offer filed by Eli Lilly and Company, signaling a pending close of the clinical-stage gene therapy acquisition.

ReadingLilly's intravitreal gene therapy portfolio now includes Adverum's pipeline. Closing mechanics are routine; regulatory risk is behind.

WatchWatch for integration timeline in Lilly's next earnings call. Gene therapy asset consolidation signals where Lilly is placing R&D capital.

Read full analysis → Original ↗

adverumeli lillygene therapyhealthcare

JOHNNIE BLUE Capital Markets Jun 20, 11:02 AM EDT

Multiple Sectors

MSN / Yahoo Finance / NBC DFW ↗

Activist investors now hold stakes in five public companies, proxy fights pending

Activist investors including Starboard Value, Oasis Capital Management, and others have reported significant stakes in Autodesk, Vail Resorts, Metalla Royalty, National Presto Industries, and additional names, signaling proxy contests and board overhauls in motion.

ReadingBoards sitting on asset value that public markets do not perceive are now targets. Activists will force asset sales or strategic partnerships within 12 months.

WatchWatch which activists win their first proxy fight. Momentum compounds. Second-wave targets will emerge within 30 days of the first decisive victory.

Read full analysis → Original ↗

activist investorsproxy fightscapital marketsboard control

WELL POUR Capital Markets Jun 20, 11:02 AM EDT

Moody's / US Government

China Daily / MSN ↗

Moody's downgraded US sovereign debt, warns Washington state on reserves

Moody's Investors Service downgraded the United States' sovereign credit rating from Aaa to Aa1 for the first time in over 100 years, citing fiscal concerns; separately, the agency warned Washington state it may downgrade due to repeated budget reserve depletion.

ReadingMunicipal and state borrowing costs will rise incrementally. Issuers with reserve depletion patterns will face higher coupon rates. This is not immediate; this is pricing in over the next 18 months.

WatchWatch state general obligation bond yields over the next quarter. Washington state's next issuance will anchor the new rate curve.

Read full analysis → Original ↗

moody'scredit downgradeus debtsovereign risk